AU2001247294A1 - Proteins named FCTRX and nucleic acids encoding same - Google Patents

Proteins named FCTRX and nucleic acids encoding same

Info

Publication number
AU2001247294A1
AU2001247294A1 AU2001247294A AU4729401A AU2001247294A1 AU 2001247294 A1 AU2001247294 A1 AU 2001247294A1 AU 2001247294 A AU2001247294 A AU 2001247294A AU 4729401 A AU4729401 A AU 4729401A AU 2001247294 A1 AU2001247294 A1 AU 2001247294A1
Authority
AU
Australia
Prior art keywords
sbjct
iii
query
lllll
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001247294A
Other languages
English (en)
Inventor
Elma Fernandes
John L. Herrmann
John Macdougall
Kumud Majumder
Peter S. Mezes
Vishnu Mishra
Luca Rastelli
Richard A. Shimkets
Corine A. M. Vernet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CuraGen Corp filed Critical CuraGen Corp
Publication of AU2001247294A1 publication Critical patent/AU2001247294A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
AU2001247294A 2000-03-03 2001-03-05 Proteins named FCTRX and nucleic acids encoding same Abandoned AU2001247294A1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US18671800P 2000-03-03 2000-03-03
US18659200P 2000-03-03 2000-03-03
US60186718 2000-03-03
US60186592 2000-03-03
US18729300P 2000-03-06 2000-03-06
US18729400P 2000-03-06 2000-03-06
US60187293 2000-03-06
US60187294 2000-03-06
US19040000P 2000-03-17 2000-03-17
US60190400 2000-03-17
US19601800P 2000-04-07 2000-04-07
US60196018 2000-04-07
US25954801P 2001-01-03 2001-01-03
US60259548 2001-01-03
PCT/US2001/007160 WO2001066747A2 (fr) 2000-03-03 2001-03-05 Nouvelles proteines et acides nucleiques codant lesdites proteines

Publications (1)

Publication Number Publication Date
AU2001247294A1 true AU2001247294A1 (en) 2001-09-17

Family

ID=27569209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001247294A Abandoned AU2001247294A1 (en) 2000-03-03 2001-03-05 Proteins named FCTRX and nucleic acids encoding same

Country Status (10)

Country Link
US (3) US20030087816A1 (fr)
EP (2) EP1790725A2 (fr)
JP (1) JP2003525634A (fr)
AT (1) ATE348161T1 (fr)
AU (1) AU2001247294A1 (fr)
CA (1) CA2401552A1 (fr)
DE (1) DE60125148T2 (fr)
DK (1) DK1261712T3 (fr)
ES (1) ES2278731T3 (fr)
WO (1) WO2001066747A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002248201A1 (en) * 2000-11-16 2002-08-06 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
CA2429195A1 (fr) * 2000-11-16 2002-05-23 Incyte Genomics, Inc. Proteines de la superfamille des immunoglobulines
CA2476654A1 (fr) * 2002-02-21 2003-09-04 Wyeth Domaine follistatine contenant des proteines
MXPA04011731A (es) * 2002-05-28 2005-02-14 Univ Minnesota Polipetidos cris como anticonceptivos e inhibidores de la capacitacion de espermatozoides.
TW200529870A (en) * 2003-11-20 2005-09-16 Novo Nordisk Healthcare Ag Therapeutic use of factor XI
US7405043B2 (en) * 2004-06-29 2008-07-29 Vita Genomics, Inc. Responsiveness to therapy for liver disorders
EP1831370A4 (fr) 2004-12-13 2009-08-12 Alethia Biotherapeutics Inc Sequences polynucleotidiques et polypeptidiques participant au remodelage osseux
JP2008535823A (ja) * 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
US20100028868A1 (en) * 2008-07-29 2010-02-04 Yuchi Hwang Responsiveness to Therapy for Liver Disorders
WO2018017657A1 (fr) * 2016-07-20 2018-01-25 The Johns Hopkins University Criblage de médicaments par hydrogel à gradient d'oxygène

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US6004775A (en) * 1990-08-03 1999-12-21 The Salk Institute For Biological Studies DNA encoding IGFBP-4
US5946778A (en) * 1998-08-11 1999-09-07 Mcgarity; Ronald M. Clip with retractable operating levers
EP1151101A4 (fr) * 1998-12-18 2002-10-09 Human Genome Sciences Inc Facteur-2 stimulant de prostacycline
CA2375424A1 (fr) * 1999-06-03 2000-12-14 Curagen Corporation Nouveaux polynucleotides et polypeptides les codants
WO2001019856A2 (fr) * 1999-09-13 2001-03-22 Curagen Corporation Nouvelles proteines humaines, polynucleotides codant celles-ci et procedes d'utilisation des memes

Also Published As

Publication number Publication date
US20030087816A1 (en) 2003-05-08
WO2001066747A3 (fr) 2002-07-18
US20080171046A1 (en) 2008-07-17
ES2278731T3 (es) 2007-08-16
CA2401552A1 (fr) 2001-09-15
DK1261712T3 (da) 2007-04-16
ATE348161T1 (de) 2007-01-15
DE60125148D1 (de) 2007-01-25
WO2001066747A2 (fr) 2001-09-13
DE60125148T2 (de) 2007-09-27
US20020155115A1 (en) 2002-10-24
WO2001066747A8 (fr) 2002-02-21
EP1261712B1 (fr) 2006-12-13
EP1261712A2 (fr) 2002-12-04
JP2003525634A (ja) 2003-09-02
EP1790725A2 (fr) 2007-05-30

Similar Documents

Publication Publication Date Title
WO2002006339A2 (fr) Nouvelles proteines et acides nucleiques les codant
US20030204052A1 (en) Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
AU2001247294A1 (en) Proteins named FCTRX and nucleic acids encoding same
WO2002006329A2 (fr) Nouveaux polynucléotides et polypeptides codés par eux
EP1326971A2 (fr) Proteines et acides nucleiques codant pour elles
EP1259538A2 (fr) Nouvelles proteines et acides nucleiques codant ces proteines
CA2377263A1 (fr) Polypeptides et polynucleotides les codants
EP1240195A2 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO2001059113A2 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
US20030082174A1 (en) Novel proteins and nucleic acids encoding same
US20030212255A1 (en) Novel proteins and nucleic acids encoding same
US20060211031A1 (en) Novel proteins and nucleic acids encoding same
US20030082757A1 (en) Novel proteins and nucleic acids encoding same
WO2002050275A2 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
US20030216304A1 (en) Novel proteins and nucleic acids encoding same
US20030068618A1 (en) Novel proteins and nucleic acids encoding same
WO2001088135A2 (fr) Proteines et acides nucleiques codant pour de telles proteines
WO2002006345A2 (fr) Nouvelles proteines et acides nucleiques les codant
US20030165858A1 (en) Novel GPCR-like proteins and nucleic acids encoding same
AU2007202935A1 (en) Proteins Named FCTRX and Nucleic Acids Encoding Same
WO2002010202A2 (fr) Nouvelles proteines et nouveaux acides nucleiques codant celles-ci
US20030166845A1 (en) Novel proteins and nucleic acids encoding same
US20030165829A1 (en) Novel proteins and nucleic acids encoding same
WO2002020758A2 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
AU2001283089A1 (en) Proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted